Yissum Technology Transfer Company of the Hebrew University of Jerusalem

As the commercializing arm of the Hebrew University since 1964, Yissum maintains portfolio of 900 registered patents and is currently offering 200 commercial projects for licensing

Activity:

- Licensing & Business Development
- Research & Development
- Sales & Distribution
- Other Industry Services

Product / Technology type(s) covered:

- API / chemicals
- Bio
- Cosmoceuticals
- Curative
- Devices
- Diagnostics
- Drug delivery
- Enzymes
- Generics
- FP (finished products)
- NCE (new chemical entities)
- OTC (over the counter drugs)
- Pharmaceuticals / Therapeutics
- Phyto
- Nutritionals / Vitamins
- Prescription drugs (Rx)
- Preventive
- Proteins
- Reagents
- Technology

Therapeutic targets:

- Aging
- AIDS
- Allergy
- Alzheimer's Disease
- Arthritis / Rheumato
- Asthma
- Cancer
- Cardiovascular
- Central nervous system
- Cough / Cold
- Dermatology
- Diabetes
- Epidemiology
- Gastrointestinal
- Genetics
- Geriatrics
- Hematology
- Infectious Diseases
- Men's Health
- Mental Health
- Neurology
- Obesity
- Oncology
- Ophthalmology
- Orthopedics
- Pain
- Pediatrics
- Radiology
- Reproductive Health
- Respiratory Medicine
- Stroke
- Surgery
- Tonics
- Transplant
- Urology
- Women's Health

Markets Covered

a. HeadQuarter: Israel

b. Continent(s) active: North America , Europe , Australia/New-Zealand , Near/Middle East

c. Countries active: USA, UK, Switzerland, Australia, Germany, France

Corporate data:

Number of Employees: 20

Turnover:

Amount:	Year:	Currency:
31M	2002	US Dollar

Year founded: 1964

Partners / Alliances: Bayer, Merck, Novartis, Teva, Johnson&Johnson